Mergers & Acquisitions

Greenhill's M&A practice includes some of the most experienced professionals in the industry. Drawing on that experience, we are active across the full range of M&A advisory roles:

Sell-side Advisory

Leveraging our independence and lack of conflicts, we have a strong track record in sell side advisory roles. Acting for target companies, special board committees or selling shareholders, we can operate at the heart of any process, assist in negotiations and give impartial and objective advice about the merits of bids received.

Buy-side Advisory

We have a strong record of successful buy side advisory assignments in relation to public or private target companies and are able to advise interested buyers on attractive targets through our global network of relationships.

Merger Advisory

Greenhill is well qualified to assist clients on merger transactions given the long experience of its partners and professionals, an assurance of total discretion and a lack of conflicting interests. Greenhill has a number of sizeable mergers in its list of completed transactions both in the US and internationally.

Special Advisory

Various advisory work that we undertake does not fit a conventional ‘transaction’ definition. Examples include our work advising the Australian National Rugby League Commission on the sale of television broadcast rights and work for the global partnership of Arthur Andersen in the immediate aftermath of the cases that followed the collapse of Enron. We believe that Greenhill’s independence, experience, expertise and discretion positions us well for special advisory assignments.

Cross-border Advisory

Greenhill’s network of international offices and our ‘single Firm’ operating model allow us to offer clients a seamless cross-border advisory service with a truly global perspective.

Recent Transactions

27-Mar-18
$13.0 billion
Switzerland flag
Target: 

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

26-Nov-07
$11.4 billion
United Kingdom flag
Target: 

Kelda Group plc

U.S., Singapore, U.K. flags
Acquiror: 
Citi Infrastructure Investors, GIC Special Investments, Infracapital Partners and HSBC Bank

Advised Kelda Group plc, a leading provider of water and waste water services in the UK, on a recommended cash offer from a consortium of international infrastructure investors

27-Jun-14
$11 billion+
United Kingdom flag
Target: 

TUI Travel Plc

Germany flag
Acquiror: 
TUI AG

Advised TUI AG on the merger with TUI Travel Plc creating the world’s number one integrated leisure tourism business (+Transaction value represents enterprise value of combined entity)

08-Aug-11
$11.0 billion
Australia flag
Target: 

Coal and Allied Industries Limited

Australia, Japan flags
Acquiror: 
Rio Tinto Limited / Mitsubishi Corporation

Advised Coal and Allied Industries Limited, an Australian based coal mining company, in relation to an acquisition proposal from Rio Tinto Limited and Mitsubishi Corporation to acquire all the outstanding shares in the company not already held by Rio Tinto and Mitsubishi

Pages

show all